Holen Sie sich die Stockscreener-App
12.01
1.44%
0.17
Schlusskurs vom Vortag:
$11.84
Offen:
$11.93
24-Stunden-Volumen:
936.28K
Relative Volume:
1.00
Marktkapitalisierung:
$644.10M
Einnahmen:
$59,000
Nettoeinkommen (Verlust:
$-84.74M
KGV:
-2.0628
EPS:
-5.8222
Netto-Cashflow:
$-59.69M
1W Leistung:
-10.57%
1M Leistung:
-25.26%
6M Leistung:
-10.04%
1J Leistung:
-13.60%
1-Tages-Spanne:
$11.70
$12.35
1-Wochen-Bereich:
$11.58
$13.82
52-Wochen-Spanne:
$11.58
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Firmenname
Avalo Therapeutics Inc
Sektor
Branche
Telefon
410-522-8707
Adresse
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
12.01 | 644.10M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-06 | Eingeleitet | Leerink Partners | Outperform |
| 2026-06-12 | Eingeleitet | BofA Securities | Buy |
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-04-06 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-09-17 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-05 | Eingeleitet | TD Cowen | Buy |
| 2025-08-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-25 | Eingeleitet | Jefferies | Buy |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-28 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-21 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-10-24 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-04-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options. - Stock Titan
1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind. - Stock Titan
In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options. - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires receive options to buy Avalo shares for $15.47 each - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan
AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan
Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Six new hires get options to buy 78,000 Avalo shares - Stock Titan
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com India
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com UK
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com UK
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Finanzdaten der Avalo Therapeutics Inc-Aktie (AVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avalo Therapeutics Inc-Aktie (AVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 16 '26 |
Sale |
16.33 |
12,394 |
202,437 |
39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Option Exercise |
8.04 |
10,185 |
81,887 |
50,085 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Sale |
17.62 |
10,185 |
179,457 |
39,900 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Sale |
20.00 |
679 |
13,580 |
51,776 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
52,455 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Option Exercise |
9.88 |
31,031 |
306,586 |
70,931 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Sale |
20.05 |
31,031 |
622,324 |
39,900 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 18 '26 |
Proposed Sale |
20.05 |
31,031 |
622,221 |
0 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 17 '26 |
Proposed Sale |
19.59 |
70,709 |
1,385,189 |
0 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 17 '26 |
Option Exercise |
9.88 |
40,821 |
403,311 |
81,594 |
15.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):